Reactivation of Hepatitis B in a Patient with Breast Cancer Treated Using Capecitabine

Reactivation of HBV is a well-recognized complication following immunosuppressive drug therapy in patients with past infection. The International Guidelines for HBV screening before cytotoxic or immunosuppressive therapy are controversial. The literature data does not report HBV reactivation due to capecitabine so the international guidelines no recommend prophylaxis in such situation. In this paper, we describe the history of HBV r eactivation of hepatatis B in a female patient with breast cancer treated using capecitabine observed in a Unit of Infectious Diseases of north-est of Italy .